We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Reversing Loss of miR-122 Helps Treat Liver Cancer

By LabMedica International staff writers
Posted on 01 Aug 2012
Print article
A study revealed that loss of the miR-122 molecule in liver cells might cause liver cancer and that restoring the molecule might slow tumor growth.

Liver cancer is the third leading cancer killer worldwide and new treatments are greatly needed. The animal study was led by researchers at the Ohio State University (OSU) Comprehensive Cancer Center-Arthur G. James Cancer Hospital (Columbus, USA) and OSU’s Richard J. Solove Research Institute (OSUCCC-James). The scientists examined what occurs when liver cells lack a molecule called microRNA-122 (miR-122). They found that when the molecule is missing, the liver develops fat deposits, inflammation, and tumors that resemble hepatocellular carcinoma (HCC), the most common form of liver cancer.

When the researchers synthetically restored miR-122 to nearly normal levels by delivering the miR-122 gene into liver cells, it considerably reduced the size and number of tumors, with tumors making up 8% on average of liver surface area in treated animals versus 40% in control animals.

The study was published July 23, 2012, in the Journal of Clinical Investigation. “These findings reveal that miR-122 has a critical tumor-suppressor role in the healthy liver, and they highlight the possible therapeutic value of miR-122 replacement for some patients with liver cancer,” said study leader Dr. Kalpana Ghoshal, associate professor of pathology and a member of the OSUCCC-James Experimental Therapeutics Program.

MiR-122 is found principally in liver cells--it is the most plentiful microRNA in those cells--and it plays a major role in regulating cholesterol in the body. This microRNA is lost in some people with HCC, however, resulting in a poor prognosis.

For this study, Dr. Ghoshal and her colleagues developed a strain of mice that lacks miR-122 and develops HCC through the progression of events that begins with fatty liver deposits followed by inflammation and liver cancer. The researchers then used a second strain of mice that spontaneously develops liver cancer due to overexpression of a cancer-causing gene called MYC. The researchers delivered miR-122 into the animals’ livers during tumor development. Three weeks later, those treated with the molecule had smaller and fewer tumors. “The model we developed for these studies will not only facilitate our understanding of liver biology, but it will also be good for testing therapeutic efficacy of newly developed drugs against liver disease, including HCC,” Dr. Ghoshal stated.

Dr. Ghoshal also noted that research by other scientists has shown that Hepatitis C virus requires miR-122 for replication. “Because our findings demonstrate what happens when miR-122 is lost in liver cells, they might help improve the safety of new drugs that treat Hepatitis C virus infection by blocking miR-122,” she concluded.

Related Links:

Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.